NASDAQ:MESOMesoblast Stock Price, Forecast & News

Mesoblast's stock was trading at $6.0250 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MESO shares have increased by 96.0% and is now trading at $11.81.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mesoblast.

Mesoblast is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020.
View our earnings forecast for Mesoblast.

Mesoblast limited (NASDAQ:MESO) released its earnings results on Wednesday, May, 27th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). The firm earned $12.20 million during the quarter, compared to analysts' expectations of $9.38 million. Mesoblast had a negative net margin of 197.65% and a negative return on equity of 13.59%.
View Mesoblast's earnings history.

7 brokers have issued 1 year price targets for Mesoblast's stock. Their forecasts range from $6.00 to $23.00. On average, they expect Mesoblast's share price to reach $15.04 in the next twelve months. This suggests a possible upside of 27.3% from the stock's current price.
View analysts' price targets for Mesoblast.

News stories about MESO stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mesoblast earned a daily sentiment score of -4.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Mesoblast.

Mesoblast saw a increase in short interest in June. As of June 30th, there was short interest totaling 1,190,000 shares, an increase of 26.8% from the June 15th total of 938,400 shares. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is currently 1.0 days.
View Mesoblast's Short Interest.

Some companies that are related to Mesoblast include Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), bluebird bio (BLUE), Iovance Biotherapeutics (IOVA), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Ablynx (ABLYF), Relay Therapeutics (RLAY), Sorrento Therapeutics (SRNE), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI) and Fate Therapeutics (FATE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Exelixis (EXEL), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Novavax (NVAX), TherapeuticsMD (TXMD), AbbVie (ABBV) and Corbus Pharmaceuticals (CRBP).

(MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Mesoblast's stock is owned by a variety of retail and institutional investors. Top institutional investors include M&G Investment Management Ltd. (1.19%), Penbrook Management LLC (0.19%), Goldman Sachs Group Inc. (0.17%), Princeton Capital Management LLC (0.12%), Sit Investment Associates Inc. (0.03%) and Wilbanks Smith & Thomas Asset Management LLC (0.02%).

MESO stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Wilbanks Smith & Thomas Asset Management LLC, and Penbrook Management LLC.

MESO stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Sit Investment Associates Inc., Princeton Capital Management LLC, SG Americas Securities LLC, UBS Group AG, and Bank of New York Mellon Corp.

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MESO stock can currently be purchased for approximately $11.81.

Mesoblast has a market capitalization of $1.38 billion and generates $16.72 million in revenue each year. The company earns $-89,800,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Mesoblast employs 81 workers across the globe.

The official website for Mesoblast is www.mesoblast.com.

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]